Get started
Work

Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy

Year: 2012
Type: article
Study design: Clinical Trial
Abstract: Patients with myeloma receiving initial therapy with lenalidomide-based regimens can have difficulty collecting adequate stem cells. Stem cell collection can be enhanced by the CXCR-4 antagonist plerixafor. Plerixafor is typically given subcutaneously (SQ), with collection approximately 11 hours after injection to obtain maximum yield. Intravenous administration can potentially allow more rapid and predictable mobilization compared to the SQ route.
DOI: 10.1016/j.bbmt.2011.12.129
Authors: S. Kumar, J. Mikhael, M. Lacy, B. LaPlant, F. Buadi, D. Dingli, M. Gertz, T. Miceli, L. Bergsagel, S. Hayman, C. Reeder, K. Stewart, A. Dispenzieri, D. Gastineau, J. Winters
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2318052701
FWCI:
Cites:
Cited by:
Related to: 10